Alexion Pharmaceuticals secured approval Friday from the Food and Drug Administration for a new drug called Ultomiris that will be used to treat an ultra-rare blood disease and ultimately replace the biotech’s current blockbuster, Soliris.

The initial Ultomiris approval granted by FDA is to treat patients with paroxysmal nocturnal hemoglobinuria, or PNH — a rare, inherited disease in which red blood cells are destroyed by over-activation of the complement system, a part of the body’s immune system.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy